Midlatitude Plasma Bubbles Over China and Adjacent Areas During a Magnetic Storm on 8 September 2017

This paper presents observations of postsunset super plasma bubbles over China and adjacent areas during the second main phase of a storm on 8 September 2017. The signatures of the plasma bubbles can be seen or deduced from (1) deep field‐aligned total electron content depletions embedded in regional ionospheric maps derived from dense Global Navigation Satellite System networks, (2) significant equatorial and midlatitudinal plasma bite‐outs in electron density measurements on board Swarm satellites, and (3) enhancements of ionosonde virtual height and scintillation in local evening associated with strong southward interplanetary magnetic field. The bubbles/depletions covered a broad area mainly within 20°–45°N and 80°–110°E with bifurcated structures and persisted for nearly 5 hr (∼13–18 UT). One prominent feature is that the bubbles extended remarkably along the magnetic field lines in the form of depleted flux tubes, reaching up to midlatitude of around 50°N (magnetic latitude: 45.5°N) that maps to an altitude of 6,600 km over the magnetic equator. The maximum upward drift speed of the bubbles over the magnetic equator was about 700 m/s and gradually decreased with altitude and time. The possible triggering mechanism of the plasma bubbles was estimated to be storm time eastward prompt penetration electric field, while the traveling ionospheric disturbance could play a role in facilitating the latitudinal extension of the depletions.Key PointsPostsunset midlatitude plasma bubbles were observed over China and adjacent areas using GNSS TEC, Swarm Ne, and ionosonde dataThe plasma bubbles were triggered by PPEF and TID in equatorial regions and extended along the magnetic field lines to 50°N (45.5 MLAT)Plasma bubbles might reach an altitude of 6,600 km over the magnetic equator with the upper limit of upward drift speed being around 700 m/sPeer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/143723/1/swe20573.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/143723/2/swe20573_am.pd

Pretreating anaerobic fermentation liquid with calcium addition to improve short chain fatty acids extraction via in situ synthesis of layered double hydroxides

In situ synthesis of layered double hydroxides (LDHs) was proved to be an effective way to extract short chain fatty acids (SCFAs) from anaerobic fermentation liquid (AFL) as carbon source for biodenitrification, but the SCFAs content in SCFAs-LDH was unsatisfactory because of the existence of much carbonate in AFL. Pretreatment of AFL with calcium addition was investigated to remove carbonate and improve SCFAs extraction via LDHs synthesis. Results of batch tests showed that, the carbonate removal efficiency was as high as 76.6% when the calcium addition was 0.06 mol/L at pH 12. When using the optimal SCFAs/Al3+ ratio of 3.0, the total SCFAs content in SCFAs-LDH with pretreatment was improved to 46.5 mg COD/g LDH, which was 4.5 times of the control (10.4 mg COD/g LDH). These results suggest that adding calcium to AFL was an effective way to eliminate the negative effect of carbonates on SCFAs-LDH synthesis

Primary cardiac osteosarcoma in a 42-year-old woman

We describe here a 42-year-old woman who was admitted to hospital with a pedunculated mass in her left atrium. She was diagnosed with a primary cardiac osteosarcoma with special immunohistochemical characteristics. Echocardiography and computed tomography can be used to differentiate cardiac osteosarcomas from routine intracardiac tumors. The patient was treated by surgical removal of the mass. Two years later, she has shown no evidence of disease recurrence. We discuss primary osteosarcomas in the cardiac cavity and their management

Improving the stability and efficiency of anaerobic digestion of food waste using additives: a critical review

Anaerobic digestion is an effective technology to treat food waste, with methane production as renewable bioenergy. However, there are two key problems in the practical application, i.e., poor system stability and low reactor efficiency. In this paper, additives used in anaerobic digestion of food waste were systematically reviewed in view of system stability and reactor efficiency. Enzymes showed excellent property in food waste pre-hydrolysis stage with almost all macromolecular matters being rapidly resolved. Fungi fermentation process to produce hydrolytic enzymes, can be regarded as a promising and low-cost way to realize rate-limiting step elimination. It can be also concluded that adding neutralizers, buffer chemicals and some other materials are effective to maintain the pH level for practical application. Trace metals in food waste are not enough but needed for methanogens activation in long term and high loading rate operation. In addition, direct interspecies electron transfer could be much helpful for intermediate refractory organic acids degradation and methanogenesis promotion with additives of conductive materials, which is also discussed and should be studied further in anaerobic digestion of food waste. Based on literature review, a new concept is proposed for further study, suggesting that after being well liquefied with enzyme pre-hydrolysis, food waste could be co-digested with landfill leachate in a high-rate anaerobic reactor stably, resulting in a high bioenergy recovery efficiency. (C) 2018 Elsevier Ltd. All rights reserved

Selective Detection of Misfolded Tau From Postmortem Alzheimer’s Disease Brains

Tau aggregates are present in multiple neurodegenerative diseases known as “tauopathies,” including Alzheimer’s disease, Pick’s disease, progressive supranuclear palsy, and corticobasal degeneration. Such misfolded tau aggregates are therefore potential sources for selective detection and biomarker discovery. Six human tau isoforms present in brain tissues and both 3R and 4R isoforms have been observed in the neuronal inclusions. To develop selective markers for AD and related rare tauopathies, we first used an engineered tau protein fragment 4RCF as the substrate for ultrasensitive real-time quaking-induced conversion analyses (RT-QuIC). We showed that misfolded tau from diseased AD and other tauopathy brains were able to seed recombinant 4RCF substrate. We further expanded to use six individual recombinant tau isoforms as substrates to amplify misfolded tau seeds from AD brains. We demonstrated, for the first time to our knowledge, that misfolded tau from the postmortem AD brain tissues was able to specifically seed all six full-length human tau isoforms. Our results demonstrated that RT-QuIC analysis can discriminate AD and other tauopathies from non-AD normal controls. We further uncovered that 3R-tau isoforms displayed significantly faster aggregation kinetics than their 4R-tau counterparts under conditions of both no seeding and seeding with AD brain homogenates. In summary, our work offers potential new avenues of misfolded tau detection as potential biomarkers for diagnosis of AD and related tauopathies and provides new insights into isoform-specific human tau aggregation

Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia

Abstract Chronic lymphocytic leukemia (CLL), a common type of B cell chronic lymphoproliferative disorder in adults, has witnessed enormous development in its treatment in recent years. New drugs such as ibrutinib, idelalisib, and venetoclax have achieved great success in treating relapsed and refractory (R/R) CLL. In addition, with the development of immunotherapy, chimeric antigen receptor-engineered T cells (CAR-T) therapy, a novel adoptive immune treatment, has also become more and more important in treating R/R CLL. It combines the advantages of T cells and B cells via ex vivo gene transfer technology and is able to bind targets recognized by specific antibodies without antigen presentation, thus breaking the restriction of major histocompatibility complex. So far, there have been lots of studies exploring the application of CAR-T therapy in CLL. In this review, we describe the structure of chimeric antigen receptor, the preclinical, and clinical results of CAR-T therapy against CLL, along with its adverse events and advances in efficacy